Last reviewed · How we verify
Oxabact OC5 - Oxalobacter formigenes HC-1
Oxabact OC5 is a live biotherapeutic product that works by colonizing the gut with Oxalobacter formigenes HC-1, which degrades oxalate, reducing its absorption and systemic levels.
Oxabact OC5 is a live biotherapeutic product that works by colonizing the gut with Oxalobacter formigenes HC-1, which degrades oxalate, reducing its absorption and systemic levels. Used for Primary Hyperoxaluria Type 1 (PH1).
At a glance
| Generic name | Oxabact OC5 - Oxalobacter formigenes HC-1 |
|---|---|
| Sponsor | OxThera |
| Drug class | Live biotherapeutic product |
| Modality | Biologic |
| Therapeutic area | Nephrology |
| Phase | Phase 3 |
Mechanism of action
Oxalobacter formigenes HC-1 metabolizes oxalate in the gut, thereby decreasing the amount of oxalate available for absorption into the bloodstream. This can help reduce the risk of hyperoxaluria and related complications such as kidney stones.
Approved indications
- Primary Hyperoxaluria Type 1 (PH1)
Common side effects
- Gastrointestinal symptoms
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria (PHASE3)
- An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxabact OC5 - Oxalobacter formigenes HC-1 CI brief — competitive landscape report
- Oxabact OC5 - Oxalobacter formigenes HC-1 updates RSS · CI watch RSS
- OxThera portfolio CI